Capital Group leads Series E for China’s Innovent Biologics
Capital Group Private Markets (CGPM), a private equity affiliate of US-based Capital Group Companies, has led a $150 million Series E round for Chinese biopharmaceutical developer Innovent Biologics.
This is the first investment in Innovent by CGPM, which focuses on emerging markets companies in the healthcare, consumer and business services sectors. Other new investors in the round include Ally Bridge,...
More on Greater China
Latest News
China's MSA Capital backs Saudi B2B start-up
China’s MSA Capital has joined a $30.5 million round for Saudi Arabian B2B services marketplace Sary as part of a deepening Asia-Middle East agenda.
5Y, Sequoia back China app-building platform
Huoban.com, a Chinese zero-code application building platform has raised $17 million in Series B funding led by 5Y Capital and Sequoia Capital China. Challenjers Capital also took part in the round.
Apollo offers $3.1b for Australia sports betting business
Apollo Management has submitted a A$4 billion ($3.1 billion) bid for the wagering and media and gaming services businesses of Tabcorp Holdings, Australia’s largest gambling company.
Yale's David Swensen dies aged 67
David Swensen, head of the Yale University endowment who pioneered a new approach to institutional investment management, has died aged 67 following a long battle with cancer.